- Home
- ATOS
as 07-26-2024 4:00pm EST
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 149.7M | IPO Year: | 2012 |
| Target Price: | $6.13 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $2.31 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Atossa Therapeutics Inc. (ATOS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Finn Jonathan | ATOS | Director | Apr 10 '24 | Buy | $1.77 | 25,000 | $44,250.00 | 25,000 | SEC Form 4 |
Latest Atossa Therapeutics Inc. News
ATOS Breaking Stock News: Dive into ATOS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Zacks
15 days ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
GlobeNewswire
24 days ago
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
GlobeNewswire
a month ago
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Zacks
a month ago
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
GlobeNewswire
a month ago
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
ACCESSWIRE
a month ago
Sidoti Events, LLC's Virtual June Small-Cap Conference
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Compare ATOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATOS Atossa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.